Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After TURP (Trans-urethral Resection of Prostate) or PVP (Photoselective Vaporization of Prostate)
PHASE4CompletedINTERVENTIONAL
Enrollment
68
Participants
Timeline
Start Date
December 4, 2012
Primary Completion Date
October 24, 2013
Study Completion Date
October 24, 2013
Conditions
Overactive BladderBenign Prostate HyperplasiaTransurethral Resection of ProstatePhotoselective Vaporization Prostatectomy
Interventions
DRUG
Solifenacin Succinate
Oral
DRUG
Placebo
Oral
Trial Locations (1)
Unknown
Seoul
All Listed Sponsors
lead
Astellas Pharma Korea, Inc.
INDUSTRY
NCT01747577 - Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After TURP (Trans-urethral Resection of Prostate) or PVP (Photoselective Vaporization of Prostate) | Biotech Hunter | Biotech Hunter